Synthetic https://validator.w3.org/feed/docs/rss2.html IPO: Immuneering Corp Innovates With Bioinfomatics Dual Agonists Push Weight Loss Drug Companies Into Full Bandwagon Mode Multi-Agonist GLP-1s And Metabolic Psychiatry Immunotherapy: The Making Of A Revolution Drug Discovery and Precision Medicine Focus Of Google Cloud’s AI-powered Solutions Mapping The Protein Machinery of Cancer Cells This Scientist Focuses On How Cells Record Trauma Arc Institute Emerges After Two Years Of Development Here Are Three Promising Cell Therapy Companies Aardvark Therapeutics Gears Up for IPO with Promising Weight Loss Drug Genome Medical Raises C Round Led By Casdin, Acquires Telehealth Genetic Counseling Company Tome Biosciences Defies Biotech Gloom Goldman Estimates GLP-1 Effects Could Boost GDP by 1% Telehealth at the Forefront: The Rise of Weight-Loss Drugs U.S. Army Aims To Innovate In Waste Treatment Using Gene Editing Strand Therapeutics Wins NIH CAR-T Cell Immunotherapy Contract Video NIH To Fund $185 Million For Research Into Human Genome Functions Upstream Benefits Signal The Making Of The Next Giant Drug Class Here Are Three Biotechs With Notable Risk/Reward Profiles How Deepmind’s Protein Folding Technology Will Impact Human Therapies How CAR T Cells Are Engineered To Treat Cancers What Is Synthetic Biology? Immuno-oncology Companies Raised $46 Billion In Recent Years Here Are Three Clinical Stage GLP-1 Agonist Weight Loss Biotechs Mayo Clinic Reports mRNA Progress In Cancer Treatment Here Are Two Compelling Therapeutic Strategies Involving GLP-1 Combinations Here Are Two Upcoming Bladder Cancer Therapies Goldman Sachs Launches First-Ever Biotech Fund mRNA Vaccine Shows Promise Against Melanoma CG Oncology Enters Bladder Cancer Therapy Space With IPO An Interview With NeuroBo’s CEO To Discuss The Company’s GLP-1 Dual Agonist Why Acasti Pharma Deserves A Deeper Look Early-Stage Colon Cancer’s Cloak of Invisibility: Unmasking SOX17 Interview with Lew Bender, President of Intensity Therapeutics Thirst Is a System Prompt CRISPR-Based Therapies Revolutionize the Treatment of Sickle Cell Disease, Underwhelm Investors If We Made Life In A Lab, Would We Understand It Differently? The Abscopal Effect in Oncology and the Role of Intensity Therapeutics In Conversation: Matthew McKnight, Chief Commercial Officer, Ginkgo Bioworks Pfizer Will Collaborate With Beam Therapeutics For In Vivo Base Editing Here Is A Promising Non-Toxic CAR-T Therapy Biotech The Future of Cancer Treatment: The Three Most Promising Emerging Therapies Sherlock Biosciences To Bring SynBio Into Homes aTyr Pharma: A Small Cap with Big Ideas in Inflammatory Diseases This Study Seeks to Prevent Cancer By Targeting Genetic Risk For Ovarian Cancer What Is Viking Therapeutics Worth? Insider Insights: Evaluating the Investment Risks of Beam Therapeutics vs. Intensity Therapeutics Ohalo Genetics Emerges From Stealth Chinese Firm’s Collection Of Global Prenatal DNA Could Fuel Ethno-Nationalist Aims